As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at one noteworthy recent insider buys.
And at Editas Medicine, there was insider buying on Friday, by Director Boris Nikolic who purchased 35,000 shares at a cost of $14.07 each, for a trade totaling $492,527. This purchase marks the first one filed by Nikolic in the past twelve months. Editas Medicine is trading up about 6.1% on the day Wednesday. Nikolic was up about 9.6% on the buy at the high point of today's trading session, with EDIT trading as high as $15.42 in trading on Wednesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.